Valuation : Edesa Biotech, Inc.

Market Cap 64.31M 55.32M 51.94M 47.55M 88.69M 6.08B 89.31M 613M 239M 3.11B 241M 236M 10.02B P/E 2026 *
-2.4x
P/E 2027 * -2.3x
Enterprise Value 64.31M 55.32M 51.94M 47.55M 88.69M 6.08B 89.31M 613M 239M 3.11B 241M 236M 10.02B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
86.54%
Yield 2026 *
-
Yield 2027 * -
1 week-3.64%
Current month+0.53%
1 month-6.85%
3 months-30.31%
6 months+108.77%
Current year+235.21%
1 week 4.45
Extreme 4.45
5.05
1 month 4.12
Extreme 4.12
6.67
Current year 0.72
Extreme 0.72
20.32
1 year 0.72
Extreme 0.72
20.32
3 years 0.72
Extreme 0.72
20.32
5 years 0.72
Extreme 0.72
84
10 years 0.72
Extreme 0.72
133.7
Manager TitleAgeSince
Chief Executive Officer 55 2015-07-31
Director of Finance/CFO 57 2025-04-30
President 48 2019-06-06
Director TitleAgeSince
Chairman 50 2019-06-06
Director/Board Member 55 2019-06-06
Chairman 70 -
Date Insider Type Main position Quantity % Market Cap. Importance
9/1/26 Free

Founder

5,714 0.0593%
8/3/26 Free

Founder

5,324 0.0553%
7/2/26 Free

Founder

3,378 0.0380%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-3.64%+103.33%-18.76% 64.31M
+0.41%-1.65%+39.85%+95.40% 68.87B
+1.31%+1.65%+50.56%+90.80% 65.29B
+0.04%+1.84%-12.81%+459.54% 27.65B
+2.97%-0.10%+41.86%+14.84% 25.77B
-0.90%-8.60%+2.25%-15.50% 26.08B
+1.01%+1.76%+32.99%-17.16% 20.14B
+3.45%-14.83%+225.22%+389.50% 17.03B
+0.77%-4.55%-0.36%+549.41% 15.03B
+1.03%+5.40%+59.04%+160.03% 14.5B
Average +1.01%-2.56%+54.19%+170.81% 28.04B
Weighted average by Cap. +0.98%-1.64%+43.45%+149.94%

Financials

2026 *2027 *
Net sales - -
Net income -17.52M -15.07M -14.15M -12.96M -24.17M -1.66B -24.34M -167M -65.13M -848M -65.8M -64.36M -2.73B -29.25M -25.16M -23.62M -21.63M -40.34M -2.76B -40.62M -279M -109M -1.42B -110M -107M -4.56B
Net Debt - -
Logo Edesa Biotech, Inc.
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.
Employees
-
Date Price Change Volume
26-09-03 US$4.760 0.00% 26,224
26-09-02 US$4.760 -0.42% 29,813
26-09-01 US$4.780 +0.95% 24,179
26-08-31 US$4.735 +2.49% 91,748
26-08-28 US$4.620 +0.43% 70,656
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.760USD
Average target price
16.33USD
Spread / Average Target
+243.14%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EDSA Stock